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Objectives: To determine whether preoperative hypercoagulable abnormalities are independent risk-factors for the failure 
of arterial reconstruction i  leg ischaemia. 
Methods: Sixty consecutive patients were studied before, and for 1 year following, elective peripheral revascularisation. 
Antithrombin III, protein C and protein S levels, and tests for lupus anticoagulant were performed preoperatively, and 
then repeated on the first and third postoperative days and after 1 and 6 months. Heparin-associated thrombocytopenia 
was also investigated if there was a postoperative fall in platelet count greater than 100 x 109/l. 
Results: Forty-six (77%) procedures were performed for critical ischaemia nd 15 (25%) involved infrapopliteal 
reconstruction. The nature of surgery or accepted risk factors for occlusion were comparable between the 40 (67%) patients 
with patent reconstructions ati year and the 20 (33%) who had suffered failure. Preoperative hypercoagulable abnormalities 
were detected in 21 (35%) patients, with a three times greater incidence in those whose reconstructions failed (65% vs. 
20%, p<O.O1), and in 11 of 12 patients uffering early (within 1 month) occlusion, The lupus anticoagulant was more 
frequently detected when prosthetic grafts were already present (Io<0.05) and carried a positive predictive value for 
reocclusion of 67% (p<O,01). All three postoperative d aths occurred in patients with low protein S levels before surgery. 
Conclusions: Hypercoagulable abnormalities are common prior to arterial revascularisation and are independently 
associated with subsequent failure. 
Key Words: Hypercoagulable states; Arterial reconstruction; Graft occlusion. 
Introduction 
Hypercoagulable states are increasingly reported in 
patients with peripheral arterial disease 1-8 and may be 
associated with the failure of revascularisation. 1-5'9'1° 
The purpose of this prospective study was to in- 
vestigate whether preoperative hypercoagulable ab- 
normalities are independently related to failure of 
arterial reconstruction, and to document the levels of 
natural anticoagulants following revascularisation for
leg ischaemia. 
Patients and Methods 
Sixty consecutive patients undergoing planned arterial 
revascularisation f r stable leg ischaemia between Jan- 
uary 1992 and November 1993 were studied. Patients 
undergoing prophylactic bypass for popliteal or an- 
astomotic aneurysms, or emergency revascularisation 
* Please address all correspondence to: S.A. Ray, 48 Lysias Road, 
London SW12 8BP, U.K. 
for acute limb ischaemia, were excluded. All patients 
underwent peroperative completion arteriography to
exclude technical deficiencies and were administered 
5000 IU subcutaneous heparin twice daily until mobile, 
and 150mg aspirin daily. The day before surgery 
venous blood was drawn for routine blood screen 
measurements and a thrombophilia screen (see below). 
Sampling was repeated on the first and third post- 
operative day, and then again after 1 and 6 months. 
At each of these visits continuing patency of the arterial 
reconstruction was ascertained by a sustained post- 
operative improvement of ankle-brachial pressure 
index of 0.15 or more and, where doubtful, confirmed 
by digital subtraction angiography. Patients were dis- 
charged from this study 1 year following re- 
construction. 
Blood samples 
A 20 ml volume of venous blood was taken for routine 
screen including haematocrit, platelet count, liver func- 
tion, and levels of serum cholesterol and triglyceride. 
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A further 10 ml was drawn into 5 ml vacuum tubes 
containing 0.5 ml 0.11 mmol/ l  sodium citrate, double- 
spun at 5°C and 300 rpm for 20 min, and stored at 
-70  ° C. Samples were later thawed and assayed in 
batches for a thrombophilia screen, which consisted 
of: 
(1) A clotting screen (prothrombin time, kaolin partial 
thromboplastin time and thrombin time) with cor- 
rection tests where appropriate. 
(2) Functional (chromogenic) assays of antithrombin 
III and activated protein C (Immunochrom PC/ 
AT III; Immuno, Vienna, Austria) 
(3) Immunological (enzyme-linked immunosorbent) 
assay of free protein S after precipitation of bound 
protein S with polyethylene glycol. 11 
(4) Tests for lupus anticoagulant including a dilute 
Russell viper venom test 12 with phospholipid neut- 
ralisation step and a kaolin clotting time. 
All assays have been validated in the authors' 
laboratory using 50 donors, from whom ranges were 
derived, international reference plasmas were used 
where available; protein S has no international stand- 
ard and its level is quoted as a percentage of normal 
plasma concentrations. 
such abnormalities increased the 1 year failure rate of 
reconstruction from 30 to 60% it was calculated that 
a minimum of 50 patients would be required to show 
a statistical difference at the 95% level. 
Twelve months following surgery patients were al- 
located to the Patent group if their reconstruction was 
still functioning and to the Occluded group if it had 
failed. The two groups were compared with respect 
to the prevalence of accepted risk factors for bypass 
occlusion, the nature of revascularisation, the pre- 
operative white blood cell count and hypercoagulable 
abnormalities. Discrete variables were analysed using 
the Chi-squared test with Yates' correction where 
necessary. The Student -test or Mann-Whitney U-test 
were used for comparing continuous variables. The 
calculation of independent risk factors for occlusion 
was performed by logistic regression analysis using an 
SAS programme (SAS Institute Incorporated, U.S.A.). 
Results 
Preoperative patient characteristics and previous 
revascularisation 
Interpretation of assays 
Protein C, protein S and antithrombin III assays were 
performed twice on the same sample. If any level was 
less than the laboratory normal range of 70-130 units/ 
dl (70-130% for protein S) the test was reported as 
abnormal and repeated at a later date when possible. 
Protein C and S levels were not interpreted if patients 
were receiving warfarin whilst antithrombin III levels 
were not performed if the patients were receiving 
intravenous heparin. These patients were still included 
since other hypercoagulable abnormalities could be 
tested. Heparin-associated thrombocytopaenia was 
suspected if there was a fall in platelet count of more 
than 100 x 109/1 from the preoperative count and con- 
firmed by the observation ofplatelet aggregation when 
mixing patient serum with donor platelets in the pres- 
ence of heparin. 13 
Analysis of results 
On the basis of a prevalence study at our unit 1 it was 
estimated that at least 25% of recruited patients would 
have a hypercoagulable abnormality. Assuming that 
Sixteen (27%) of the 60 patients undergoing peripheral 
arterial reconstruction were diabetic and 23 (38%) were 
smokers at the time of admission. Forty-six (77%) of 
the procedures were performed for ischaemic rest pain 
or ulceration whilst the remainder had re- 
vascularisation to alleviate disabling claudication. 
Thirty-eight (63%) patients had a history of previous 
surgical or percutaneous revascularisation. Twenty- 
five (42%) had undergone up to three surgical re- 
constructions and in 14 patients prosthetic graft ma- 
terial was still present. Nineteen (32%) patients had 
undergone up to four percutaneous attempts at re- 
lieving peripheral ischaemia, and this had involved 
thrombolysis n five cases. 
Postoperative clinical course 
Failure of arterial reconstruction was suffered by 20 
(33%) patients (Occluded group) after a median post- 
operative interval of 2 weeks (range i day to 7 months 
following surgery). Twelve of these occurred within 1 
month of surgery. One patient died from a post- 
operative myocardial infarct and another died within 
the follow-up period. Seven required major am- 
putation (3 below-knee, I through-knee, 3 above-knee) 
and five had further reconstructive surgery. Of the 40 
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Table 1. Characteristics of patients with patent or occluded re- 
construct ions I year following surgery. 
Patent Occluded 
(n =40) (n=20) 
Male:female 27:13 12:8 
Age (years + range) 69.3 (29-85) 64.6 (49-89) 
Diabetic (%) 11 (27) 5 (25) 
Smokers (%) 15 (37) 8 (40) 
Limb-threatening schaemia (%) 32 (80) 14 (70) 
Aortic/iliac 2 (5) 1 (5) 
reconstruction (%) 
Femoropopliteal bypass: 
Vein (%) 4 (10) 1 (5) 
Prosthetic (%) 13 (32.5) 6 (30) 
Femorodistal bypass: 
Vein (%) 8 (20) 2 (10) 
Prosthetic (%) 3 (7.5) 1 (5) 
Thrombectomy (%) 3 (7.5) 4 (20) 
Extra-anatomical bypass (%) 7 (17.5) 5 (25) 
(67%) patients who did not suffer failure (Patent group) 
two patients died postoperatively, one following a 
myocardial infarction and the other from renal failure 
following removal of an infected aortic graft and extra- 
anatomical bypass. A further three patients died dur- 
ing the follow-up period. Of the remaining 35 patients, 
four required below-knee amputations for intractable 
leg ulceration and gangrene despite a functioning 
graft. Table 1 shows the patient characteristics, in- 
dications for intervention and nature of arterial re- 
construction i the Patent and Occluded groups. There 
was an increased proportion of femorodistal re- 
constructions in the Patent group and of surgical 
thrombectomy in the Occluded group but these were 
not statistically significant. 
Causes of failed reconstruction 
Duplex ultrasound surveillance of reconstruction was 
not available during the study period and there was 
no information on graft haemodynamics before failure. 
In two patients the anatomical cause of failure was 
not sought as reintervention was not contemplated. 
Two more patients had a failed attempt at throm- 
bolysis. In the remaining 16 patients imaging during 
arteriography or direct inspection at re-operation en- 
abled the probable cause of failure to be identified 
in eight cases: three patients had significant intimal 
hyperplasia t proximal or distal anastomoses and 
three more had progression of distal atheroma. One 
patient had a kink in a PTFE graft and another had a 
stenosed valve in a reversed saphenous vein graft. In 
the remaining eight patients there was no obvious 
anatomic reason for failure. 
Nature of hypercoagulable abnormalities before surgery 
Hypercoagulable abnormalities were found in 21 (35%) 
of the patients before surgery. Only one patient had a 
low antithrombin III level, 53 units/dl,  compared to 
mean (S.D.) levels in the other patients of 101.3 units/ 
dl (20.5). Six patients were taking warfarin prior to 
surgery but protein C and S levels were available for 
interpretation i 54 patients. Three patients had low 
protein C levels (mean + S.D. = 60 + 12.2%) in contrast 
to mean (S.D.) levels of 97.7% (19.6) in those classified 
as normal (t =3.3, 52 df, p = 0.002). Ten patients had 
low levels of protein S (mean+s.D. = 59.7 +17.7%) 
whilst a level of 109.4% (27.1) was noted in the re- 
mainder (t=5.8, 52 df, p<0.0001). None of the nine 
patients with the lupus anticoagulant had systemic 
lupus erythematosis and the KCCT in all cases was 
normal (median 41 s; range 32-47 s). 
Heparin-associated hrombocytopenia 
Heparin-associated thrombocytopenia w s tested for 
in four patients and detected in two. The first was a 
64-year-old woman being treated with intravenous 
heparin for deep venous thrombosis. Ischaemia de- 
veloped in the same leg and necessitated iliofemoral 
thrombectomy, at which a typical "white clot" of plate- 
let thrombus was retrieved. Her postoperative platelet 
count was 55 x 109/1 and reocclusion occurred the 
following day. Despite further thrombectomy and 
thrombolysis an above-knee amputation was required. 
The second patien t was a 38-year-old iabetic woman 
who developed an ischaemic foot during admission 
for ketoacidosis. This was initially treated with intra- 
venous heparin and arteriography demonstrated infra- 
popliteal thrombus which did not respond to lytic 
agents. Surgical thrombectomy revealed characteristic 
"white clot" of platelets in the tibioperoneal trunk. 
Platelet count was 39 x 109/1 by the third postoperative 
day. The leg ischaemia progressed proximally and 
above-knee amputation was performed, following 
which she suffered a thrombotic stroke. Heparin-as- 
sociated platelet aggregation was confirmed in both 
cases. 
Significance of preoperative hypercoagulable abnormality 
Nearly 40% of the study patients who had undergone 
a previous revascularisation procedure had a hy- 
percoagulable abnormality in contrast to 27% of those 
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Table 2. Hypercoagulable abnormalities present before re- 
vascularisation for leg ischaemia in patients with patent or oc- 
cluded reconstructions. 
Patent Occluded 
(n =40) (n =20) 
Low antithrombin III (%) 0 1 (5) 
Low protein C (%) 1 (2) 2 (10) 
Low protein S (%) 6 (15) 4 (20) 
Lupus anticoagulant (%) 2 (5) 7 (35)* 
Heparin-associated 0 2 (10) 
thrombocytopenia (%) 
Any abnormality (%) 8 (20) 13 (65) t
* Chi-squared =7.21, 1df, p<0.01 
Chi-squared = 11.87, 1 df, p<0.01 
who had never before required intervention (Chi- 
squared = 0.91, 1 df, p = 0.34). There was no significant 
difference in preoperative l vels of protein C, protein 
S or antithrombin III between those patients with an 
old bypass graft in situ and those without. However, 
the lupus anticoagulant was detected four times more 
frequently (36% vs. 9%, Chi-squared =4.21, p<0.05) in 
the 14 patients with a prosthetic graft in situ. 
There was no significant difference in the prevalence 
of preoperative hypercoagulable abnormalities be- 
tween diabetics and non-diabetics (45% vs. 31%, Chi- 
squared=0.73, 1 df, p=0.39), smokers and non- 
smokers (35% vs. 40%, Chi-squared =0.06, 1 dL p = 
0.81), and claudicants and patients with ischaemic rest 
pain or ulceration (33% vs. 45%, Chi-squared =0.15, 1 
df, p = 0.70). 
Table 2 compares the hypercoagulable abnormalities 
detected prior to surgery in the Patent and Occluded 
groups. Overall, abnormalities were detected over 
three times more frequently in the Occluded than 
Patent groups (p<0.01) with the lupus anticoagulant 
being found seven times more often in the Occlusion 
group (p<0.01). Of the 12 patients suffering failure 
within 1 month of surgery preoperative hyper- 
coagulable abnormalities were found in 11 (92%), 
nearly four times more frequently than that found in 
the eight patients whose reconstruction failed after the 
first postoperative month (92% vs. 25%, Chi-squared =
6.68, p<0.01). Table 3 demonstrates that the only in- 
dependent variable significantly associated with fail- 
ure of reconstructive surgery was a pre-existing 
hypercoagulable abnormality, usually due to the effect 
of the lupus anticoagulant. Smokers and diabetics were 
also more likely to suffer reconstruction failure but 
this was not significant. 
Table 4 lists details of the eight patients in whom 
there was no apparent reason at imaging or operation 
for the failure of reconstruction. Five were female, 
contrasting with the male predominance of the study 
Table 3. Independent r isk factors for postoperative failure of 
reconstruction. 
Odds ratio 95% confidence 
interval 
Smoker 1.9 
Diabetic 1.5 
Limb-threatening ischaemia 1.1 
Femorotibial bypass 0.9 
Preoperative hypercoagulable 6.6 
abnormality 
*p<0.01 
0.1-2.2 
0.3-6.4 
0.3-5.3 
0.1-1.9 
1.7-25.5" 
group as a whole. Furthermore, they were ap- 
proximately a decade younger than patients who had 
an identifiable cause for failure of arterial re- 
construction (58.6 vs. 68.2 years, t= 1.63, p = 0.12). Five 
of the eight patients had a preoperative hy- 
percoagulable abnormality, and two of these had more 
than one abnormality. Of the remaining three patients 
with normal preoperative thrombophilia screens, one 
had already undergone several revascularisation pro- 
cedures and also suffered from Crohn's disease. An- 
other was receiving chemotherapy for oesophageal 
carcinoma. 
The three patients who died postoperatively all had 
low preoperative protein S levels (50%, 63%, 66%), 
significantly different from preoperative protein S 
levels in the surviving 57 patients (59.7% vs. 103.8%; 
t=2.5, 52 d.f., p=0.02). All three had undergone re- 
vascularisation for either rest pain or ischaemic ul- 
ceration. A low protein S level before surgery was 
significantly associated with postoperative death (Chi- 
squared = 10.11, 1 d.f., p=0.002). 
Changes in hypercoagulable abnormalities following 
surgery 
Figure 1 shows the prevalence of hypercoagulable 
abnormalities during the 6 months following surgical 
revascularisation for leg ischaemia. By the third post- 
operative day the majority of patients had an ab- 
normality, usually of the natural anticoagulants protein 
C or protein S. Six months following surgery the only 
abnormalities detected were of a low protein S or the 
lupus anticoagulant. Figure 2 shows the prevalence of 
any hypercoagulable abnormality before and for 6 
months following surgery in both the Patent and Oc- 
cluded groups. There was no further increase in the 
prevalence of abnormalities in the Occluded group in 
the early postoperative period, although the nature of 
abnormalities did change with those of the natural 
anticoagulants predominating. The different pre- 
valence of hypercoagulable abnormalities between the 
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Table 4. Characteristics of eight patients suffering failure of reconstruction with no demonstrable cause. 
Name Sex Age Nature of graft or Previous Time to Relevant Pre-op screen 
(years) reconstruction surgery occlusion comments 
JH M 56 R axilloprofunda Aorto bifemoral 1 week Low PC 
(infected) Low PS 
Low ATIII 
JS F 69 5 days Previous Low PC 
DVT Low PS 
L iliopopliteal L femoro 
popliteal (PTFE) 
Graft 
thrombectomy 
Graft lysis 
HS M 63 R femoropopliteal R femoro 3 months Normal 
(PTFE) popliteal (PTFE) 
Graft 
thrombectomy 
GN F 58 Aortic graft Aorto bifemoral 1 day Lupus 
thrombectomy Femoro femoral anticoagulant 
(PTFE) 
GD F 47 L iliofemoral (PTFE) R femoral 2 days Crohn's Normal 
embolectomy/ disease 
thrombectomy/ 
lysis/re- 
thrombectomy 
L SFA 
thrombectomy 
GW F 62 R femoro-L profunda Bilateral femoro 2 months Carcinoma Normal 
crossover (PTFE) popliteal oesophagus 
RL M 73 L femoro popliteal Bilateral iliac 1 month On Fragmin Low PS 
(composite) angioplasty post- 
discharge 
DO F 38 L popliteal None 1 day Heparinised Heparin- 
embolectomy post-op associated 
thrombocyto 
pania 
PC = protein C; PS = protein S; ATIII = antithrombin III. 
60 
,.Q 
50 
40-  
30 
20-  
10 
l 
pre-op Day  1 Day  3 1 month  6 months  
Fig. 1. Prevalence of hypercoagulable abnormalities following peripheral arterial reconstruction. (O) any abnormality; (O) low protein S; 
( . )  low protein C; (D) low antithrombin III; (A) lupus anticoagulant. 
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pre-op Day 1 Day 3 1 month 6 months 
Fig. 2. Prevalence ofhypercoagulable abnormalities following peripheral rterial reconstruction in Patent and Occluded groups. (©) 
patent; (0) occluded. 
Patent and Occluded groups was maximal before re- 
construction. 
Discussion 
In a previous study we noted that patients with a 
failed peripheral arterial reconstruction were more 
likely to have hypercoagulable abnormalities than 
those with patent grafts. 1 Prospective studies have 
confirmed the association between preoperative hy- 
percoagulable abnormalities and subsequent graft fail- 
ure but neither the nature of the revascularisation, nor 
the role of other risk factors for occlusion, have been 
simultaneously analysed. 2'3 The relatively high failure 
rate following arterial reconstruction i this study is 
consistent with previous figures from this and other 
units 14'15 and may reflect he high proportion of limb- 
salvage procedures (77%) and tibial anastomoses 
(23%). The high proportion of inserted prosthetic grafts 
(38%) reflects imilar published patency rates to vein 
grafts above the knee, and a lack of suitable autogenous 
vein for four distal bypasses. However, all prosthetic 
bypasses below the knee had an adjuvant venous 
anastomotic patch and the proportion of such grafts 
in the Patent and Occluded groups was similar. There 
was no ultrasound graft surveillance at the time but 
in only two cases were technical deficiencies thought 
to be a significant factor in occlusion. 
The high prevalence of hypercoagulable ab- 
normalities detected prior to surgery in this study 
(35%) is similar to that reported in clinically stable 
claudicants attending our unit ~ and therefore unlikely 
to be related to the consumption of natural anti- 
coagulants during acute ischaemia. Certainly there 
was no significant difference in the prevalence of 
abnormalities in this study between claudicants and 
those with more severe ischaemia. Furthermore, 11 of 
the 21 patients with hypercoagulable abnormalities 
had the lupus anticoagulant or heparin-associated 
thrombocytopaenia, which are not precipitated by 
ischaemic hanges or thrombosis per se. 
Natural anticoagulant levels decreased following 
revascularisation, with over 50% of patients becoming 
deficient in protein C, protein S or antithrombin III 
(Fig. 1). Protein C and antithrombin III levels were 
restored one month later but protein S took longer. 
Postoperative falls of 10-30% in both antithrombin 
II116'I7 and protein C x8 have been noted previously 
with the nadir on the third postoperative day and 
restoration to normal levels by 1 week. ~7'18 There are 
several hypotheses for the decrease in natural anti- 
coagulants following surgery: tissue damage induces 
low-grade DIC with increased circulating thrombin 19 
and increased activation and consumption of protein 
C. Blood loss during surgery may also decrease the 
pool of natural anticoagulants, 2° which is not re- 
plenished by transfusion. I6 
In this study the detection of a hypercoagulable 
abnormality before revascularisation was in- 
dependently predictive of subsequent failure of arterial 
reconstruction. Postoperative measurements were of 
less predictive value (Fig. 2). Although this unit has 
previously found the preoperative white blood cell 
count to be independently predictive of femo- 
ropopliteal graft failure, 14 we only studied 24 such 
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procedures and were unable to confirm or refute this 
finding. Neither smoking nor diabetes was sig- 
nificantly associated with postoperative failure of re- 
construction. This appears to be contrary to some 
published ata 21 but may be reconciled by the relatively 
short time to failure in this study. Wiseman et al. have 
also reported no difference in the patency rates 6 
months following femoropopliteal vein bypass in those 
with serum markers of continued smoking and those 
confirmed to be non-smokers. 2~The adverse ffects of 
smoking and diabetes are predominantly mediated 
via the progression of atherosclerosis which is thought 
to be the principal cause of late graft failure. 22'23 By 
contrast hypercoagulable abnormalities appear to be 
of greatest significance in early (within 1 month) fail- 
ure. The most important abnormalities in this respect 
was the lupus anticoagulant which was detected in 
nine (15%) patients. Previous investigators have re- 
ported the presence of the lupus anticoagulant in 
between 3.5 and 45% of arteriopaths. 2'5's'24 This large 
variation in prevalence is at least partly due to the 
method of identifying the lupus anticoagulant. For 
example, Fligelstone t al. noted that use of a prolonged 
activated partial thromboplastin time alone to screen 
for the lupus anticoagulant would have identified only 
12% of the cases discovered by the currently accepted 
tests, s In this study we also used the dilute Russell 
viper venom time to detect he lupus anticoagulant as
recommended by both national 25 and international 26 
working parties. None of these patients had an ab- 
normal KCCT. 
In our study the lupus anticoagulant carried a pos- 
itive predictive value for reconstructive failure of 67% 
in this study (Chi-squared =4.24, 1 df, p<0.05). Taylor 
et al. found that arteriopaths with anti-phospholipid 
antibodies (anticardiolipin or the lupus antibodies) 
were 1.8 times as likely to have had previous lower 
extremity revascularisation (p<0.05) and 5.6 times as 
likely to have suffered failure of that procedure 
(p<0.01) than patients who did not have these anti- 
bodies, s We have previously postulated that the lupus 
anticoagulant may appear as a result of exposure to 
prosthetic material ~and in this study it was detected 
four times more frequently in patients with prosthetic 
grafts in  situ. 
Thirty-eight percent of patients with preoperative 
hypercoagulable abnormalities did not suffer re- 
occlusion which suggests that other factors such as a 
low-flow state or a technical deficiency may be re- 
quired before the reconstruction is at risk. Alternatively 
multiple abnormalities per se may jeopardise arterial 
reconstruction. For example two of the three patients 
with two or more hypercoagulable abnormalities be- 
fore reconstruction suffered occlusion for no apparent 
other reason (Table 4). Up to 20% of graft failures do 
not have an obvious cause 27 and some of these may 
represent spontaneous thrombosis resulting from a 
hypercoagulable state. It is not clear why three patients 
suffered occlusion despite a normal thrombophilia 
screen (Table 4) but two had systemic illnesses which 
are associated with a tendency to thrombosis. TM They 
may have had underlying hypercoagulable ab- 
normalities for which tests were not available at the 
start of the study, for example activated protein C 
resistance. 
An unexpected finding was the association of a low 
protein S level and postoperative mortality, However, 
all three cases had limb-threatening ischaemia which 
carries a higher mortality than surgery for claudication. 
In two of the patients the cause of death was ischaemic 
heart disease. There is little information on the as- 
sociation of hypercoagulable abnormalities with cor- 
onary artery disease but a similar mechanism may 
operate to that in peripheral vessels. 
This study demonstrates that hypercoagulable ab- 
normalities, in particular the lupus anticoagulant, are 
common prior to arterial reconstruction for leg isch- 
aemia and are independently predictive of subsequent 
failure. However, it is not clear what action should be 
taken if an abnormality is detected. Nitecki et al. advise 
avoidance of surgical revascularisation wherever pos- 
sible. 4 If surgery is mandatory most investigators re- 
commend careful anticoagulation 4'a8'29 although there 
is no supporting data for this. Protein C deficiency 
has also been treated with plasma replacement 3° or 
anabolic steroids, 31 whilst prednisolone and aspirin 
therapy, in addition to anticoagulation, have been 
suggested for the treatment ofthe lupus anticoagulant. 9 
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